Q4 2025 LENZ Therapeutics Inc Earnings Call Transcript
Key Points
- LENZ Therapeutics Inc (LENZ) reported strong financial health, ending 2025 with over $292 million in cash, providing significant resources for future investments.
- The company has successfully launched VIZZ, a novel treatment for presbyopia, with over 45,000 boxes sold and more than 10,000 prescribing eye care professionals (ECPs).
- Early patient feedback indicates that VIZZ works quickly, with effects noticeable within 30 minutes and lasting throughout the workday.
- The direct-to-consumer campaign featuring Sarah Jessica Parker is driving significant consumer engagement, with website traffic increasing up to 10 times during national activations.
- LENZ Therapeutics Inc (LENZ) is expanding its sales force to 117 representatives to increase physician engagement and accelerate product adoption.
- The launch of VIZZ is still in its early stages, and new patient adoption is developing gradually, which is typical for new treatment categories.
- LENZ Therapeutics Inc (LENZ) faces challenges in changing physician perceptions, as some doctors still view VIZZ as suitable only for early presbyopes.
- The company reported a net loss of $35.9 million in Q4 2025, with a net loss per share of $1.16, compared to a net loss of $12.7 million in the same period in 2024.
- Operating expenses increased significantly to $40 million in Q4 2025, driven by the establishment of the sales force and the launch of VIZZ.
- LENZ Therapeutics Inc (LENZ) anticipates that it will take at least two quarters for the direct-to-consumer campaign to translate into prescription trends, indicating a delay in seeing tangible results from marketing efforts.
Ladies and gentlemen, and welcome to the LENZ Therapeutics year end 2025 financial conference call. (Operator Instructions)
I can turn the call over to Dan. Please.
Thank you. Good morning and thank you for joining us today. My name is Dan Chevallard, Chief Financial Officer of LENZ Therapeutics. We are joined today by Eef Schimmelpennink, our President and Chief Executive Officer, and Shawn Olsson, our Chief Commercial Officer, as well as Dr. Marc Odrich, Chief Medical Officer, who will join us for the question-and-answer session.
Before we begin, I would like to remind you that this call will contain overlooking statements regarding LENZâs future expectations, plans, prospects, corporate strategy, regulatory and commercial plans and expectations, cash runway projections, and performance.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors and risks, including those discussed in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
